Press releases

23 March, 2017

Regulatory

Notice of Annual General Meeting of Shareholders in NeuroVive Pharmaceutical AB

The Board of Directors of NeuroVive Pharmaceutical AB (publ) has issued a notice to the Annual General Meeting, which is to take place on Thursday, April 27, 2017, at 4 pm at Medicon Village, Scheelev ...

22 February, 2017

Regulatory

NeuroVive appoints recognized scientific advisors and enters research agreements in NASH and hepatocellular carcinoma

Lund, Sweden, February 22, 2017 - NeuroVive Pharmaceutical AB (Nasdaq Stockholm: NVP, OTCQX: NEVPF), the mitochondrial medicine company, today announced two new research agreements and the appointment ...

2 February, 2017

Regulatory

NeuroVive’s new generation of sanglifehrin-based compounds demonstrate potent inhibitory effects on human hepatocellular cancer cells

Lund, Sweden, February 2, 2017 - NeuroVive Pharmaceutical AB (Nasdaq Stockholm: NVP, OTCQX: NEVPF), the mitochondrial medicine company, presents preclinical data from a new generation of sanglifehrin- ...

25 January, 2017

Regulatory

NeuroVive redirects research resources from Asian subsidiary to parent

Lund, Sweden, January 25, 2017 - NeuroVive Pharmaceutical AB (Nasdaq Stockholm: NVP, OTCQX: NEVPF), the mitochondrial medicine company, today announced that its Taiwan-based subsidiary's research reso ...

23 January, 2017

Regulatory

NeuroVive signs mitochondrial medicine research agreement with US key opinion leader

Lund, Sweden, January 23, 2017 - NeuroVive Pharmaceutical AB (Nasdaq Stockholm: NVP, OTCQX: NEVPF), today announces that NeuroVive has signed a preclinical collaboration agreement with the Children's ...

19 January, 2017

Regulatory

NeuroVive presents positive preclinical data in hepatocellular cancer at HCC Summit

Lund, Sweden, January 19, 2017 - NeuroVive Pharmaceutical AB (Nasdaq Stockholm: NVP, OTCQX: NEVPF), the mitochondrial medicine company, today announced that an abstract with novel preclinical cancer d ...

10 January, 2017

Regulatory

NeuroVive signs collaboration agreement with Karolinska Institutet

Lund, Sweden, January 10, 2017 - NeuroVive Pharmaceutical AB (Nasdaq Stockholm: NVP, OTCQX: NEVPF), the mitochondrial medicine company, today announced that a collaboration agreement has been signed w ...

3 January, 2017

Regulatory

NeuroVive to Present at the 9th Annual Biotech Showcase Conference

Lund, Sweden, January 3, 2017 - NeuroVive Pharmaceutical AB (Nasdaq Stockholm: NVP, OTCQX: NEVPF), the mitochondrial medicine company, today announces that the company is scheduled to present the 9th ...

8 November, 2016

Regulatory

NeuroVive’s recruitment of Michele Tavecchio strengthens its research organization

Lund, Sweden, November 8, 2016 - NeuroVive Pharmaceutical AB (Nasdaq Stockholm: NVP, OTCQX: NEVPF), the mitochondrial medicine company, today announced that the company has recruited Michele Tavecchio ...

1 November, 2016

Regulatory

NeuroVive reports positive pre-clinical results in NASH

Lund, Sweden, November 1, 2016 - NeuroVive Pharmaceutical AB (Nasdaq Stockholm: NVP, OTCQX: NEVPF), the mitochondrial medicine company, today announced positive pre-clinical results with one of its cy ...

26 October, 2016

Regulatory

NeuroVive Pharmaceutical AB: Annual General Meeting 2017 and Nomination Committee

Lund, Sweden, October 26, 2016 - NeuroVive Pharmaceutical AB (Nasdaq Stockholm: NVP, OTCQX: NEVPF), the mitochondrial medicine company, today announces that the Annual General Meeting of NeuroVive Pha ...

25 October, 2016

Regulatory

NeuroVive completes closure of Lyon subsidiary

Lund, Sweden, October 25, 2016 - NeuroVive Pharmaceutical AB (Nasdaq Stockholm: NVP, OTCQX: NEVPF), the mitochondrial medicine company, today announced that it has completed the closure of its dormant ...